Results 281 to 290 of about 214,027 (378)

Selatogrel: Potential to redefine timely anti‐platelet intervention

British Journal of Pharmacology, Volume 182, Issue 22, Page 5435-5452, November 2025.
Acute coronary syndrome (ACS) encompasses a number of heart diseases that cause a sudden decrease in coronary perfusion, precipitating cardiomyocyte necrosis or heightened risk thereof. This pathology is a major burden of cardiovascular disease.
Rudy N. Zalzal, Peter P. Salem, Ali H. Dakroub, Ali H. Eid   +3 more
wiley   +1 more source

Irradiation with 265-nm Ultraviolet Light-Emitting Diodes to Plasma: Alterations of Hemostatic Parameters and von Willebrand Factor. [PDF]

Transfus Med Hemother
Hayashi T, Fujimura Y, Sakurai Y, Masaki M, Fuchizaki A, Oguma K, Hosokawa K, Mishima Y, Tanaka M, Yasui K, Kimura T, Tani Y, Hirayama F, Takahashi K, Takihara Y.   +14 more
europepmc   +1 more source

Von Willebrand Factor Collagen-Binding Activity and Von Willebrand Factor-Mediated Platelet Adhesion in Patients with Coronary Artery Disease. [PDF]

Biomedicines
Gabbasov Z, Okhota S, Avtaeva Y, Saburova O, Melnikov I, Shtelmakh V, Bazanovich S, Guria K, Kozlov S.   +8 more
europepmc   +1 more source

Anti‐ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

American Journal of Hematology, Volume 100, Issue 10, Page 1736-1746, October 2025.
Anti‐ADAMTS13 IgG antibodies titer trajectory from baseline to day 7–14 post‐TPE as a reliable approach to identify iTTP patients at risk of late response to the triplet therapy regimen. ABSTRACT Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have ...
Marie Robert, Arthur Mageau, Ygal Benhamou, François Provôt, Jehane Fadlallah, Lionel Galicier, Elie Azoulay, Hafid Ait‐Oufella, Tomas Urbina, Pascale Poullin, Alain Wynckel, Coralie Poulain, Nihal Martis, Pierre Perez, Virginie Rieu, Yahsou Delmas, Jean‐Michel Halimi, Christelle Barbet, Amélie Seguin, Valérie Chatelet, Jean‐François Augusto, Mathieu Legendre, Olivier Moranne, Carole Philipponnet, Bérengère Cador, Raïda Bouzid, Bérangère S. Joly, Agnès Veyradier, Paul Coppo, on behalf of the French Reference Center for Thrombotic Microangiopathies, Augusto Jean‐François, Azoulay Elie, Barbay Virginie, Benhamou Ygal, Charasse Christophe, Charvet‐Rumpler Anne, Chauveau Dominique, Ribes Davis, Choukroun Gabriel, Coindre Jean‐Philippe, Coppo Paul, Delmas Yahsou, Kwon Theresa, Salanoubat Célia, Dossier Antoine, Fain Olivier, Ville Simon, Frémeaux‐Bacchi Véronique, Galicier Lionel, Grangé Steven, Guidet Bertrand, Halimi Jean‐Michel, Hamidou Mohamed, Neel Antoine, Fornecker Luc‐Matthieu, Hié Miguel, Jacobs Frédéric, Joly Bérangère, Kanouni Tarik, Kaplanski Gilles, Rieu Claire, Le Guern Véronique, Moulin Bruno, Rebibou Jean‐Michel, Ojeda Uribe Mario, Parquet Nathalie, Pène Frédéric, Perez Pierre, Poullin Pascale, Marie Manon, Presne Claire, Provôt François, Mesnard Laurent, Saheb Samir, Seguin Amélie, Servais Aude, Stépanian Alain, Veyradier Agnès, Vigneau Cécile, Wynckel Alain, Zunic Patricia   +80 more
wiley   +1 more source

A Disintegrin and Metalloprotease with Thrombospondin Motif, Member 13, and Von Willebrand Factor in Relation to the Duality of Preeclampsia and HIV Infection. [PDF]

Int J Mol Sci
Naidoo P, Naicker T.
europepmc   +1 more source

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

Blood, 2014
M. Levade, Elodie David, Cédric Garcia, P. Laurent, Sarah Cadot, A. Michallet, J. Bordet, C. Tam, P. Sié, L. Ysebaert, B. Payrastre   +10 more
semanticscholar   +1 more source

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report

American Journal of Hematology, Volume 100, Issue 10, Page 1813-1827, October 2025.
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies.
Hanny Al‐Samkari, Raj S. Kasthuri, Hans‐Jurgen Mager, Jenny Y. Zhou, Marcelo M. Serra, Bethany T. Samuelson‐Bannow, Layla N. Van Doren, Jay F. Piccirillo, Marianne S. Clancy, Keith R. McCrae, Sonia M. Thomas, Antoni Riera‐Mestre, Allyson M. Pishko, Sarah Sewaralthahab, James R. Gossage, Vivek N. Iyer, Cedric Hermans, Adrienne Hammill, Ingrid Winship, Meir Mei‐Zahav, Annette von Drygalski, Scott Olitsky, Marie E. Faughnan   +22 more
wiley   +1 more source

Comparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database. [PDF]

Blood Vessel Thromb Hemost
Akimoto T, Inaba H, Ogishima S, Kumada K, Mitsuhashi A, Miyashita R, Yamaguchi T, Bingo M, Chikasawa Y, Shinozawa K, Hagiwara T, Amano K, Kodama EN, Kinai E.   +13 more
europepmc   +1 more source

Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease

Haemophilia, 2015
N. Rydz, J. Grabell, D. Lillicrap, P. James   +3 more
semanticscholar   +1 more source

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report

Cancer Innovation, Volume 4, Issue 5, October 2025.
The diagnosis and treatment of acquired hemolytic anemia can be challenging. In breast cancer patients, it may be directly associated with the underlying malignancy (as an initial presentation or during disease progression). The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) is often delayed, and patients have a high mortality ...
Mengyuan Li, Mao Ding, Yukun Hou, Xuening Duan, Yuanjia Cheng, Ling Xu   +5 more
wiley   +1 more source